2487 — Cutia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.51bn
- HK$969.37m
- CNY336.15m
Annual cashflow statement for Cutia Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -320 | -556 | -1,964 | -434 | -340 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 184 | 330 | 1,545 | 48.1 | 72.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -34 | -29.1 | -5.42 | -102 | -65.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -160 | -236 | -381 | -443 | -290 |
| Capital Expenditures | -25.9 | -135 | -55.9 | -25.7 | -12.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -385 | 597 | -148 | 342 | -7.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -411 | 462 | -204 | 316 | -20.3 |
| Financing Cash Flow Items | -0.148 | -3.37 | -10 | -5.98 | -2.28 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 481 | -10.2 | 588 | 37.8 | 193 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -97 | 263 | 7.25 | -87.5 | -121 |